Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: A survey of the Japan lymphoma radiation therapy group

International Journal of Radiation Oncology Biology Physics

Volumn 48, Issue 1, 2000, Pages 161-168

  Oguchi, Masahiko ^a,c   Ikeda, Hiroshi ^b,c   Isobe, Kouichi ^c   Hirota, Saeko ^c   Hasegawa, Masatoshi ^c   Nakamura, Katsumasa ^c   Sasai, Keisuke ^c   Hayabuchi, Naofumi ^c  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c Depts of Radiol and Radiat Oncol   (Japan)

Author keywords

Chemotherapy; Non Hodgkin's lymphoma; Prognostic factor; Radiation therapy; Tumor bulk

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CHEMOTHERAPY; CLINICAL TRIAL; FEMALE; HISTOLOGY; HUMAN; JAPAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RISK FACTOR; SEX DIFFERENCE; SKIN TOXICITY; SURVIVAL RATE; TUMOR VOLUME; WALDEYER RING;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; JAPAN; LEUCOVORIN; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; SURVIVAL RATE; VINCRISTINE;

EID: 0034255774     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00480-6     Document Type: Article

References (23)

1. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 329:1993;987-994.
2. Rodriguez J, Cabanillas F, MacLaughlin P; et al. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. Ann Oncol 1992;3:711-717.
3. Velasquez W.S., Fuller L.M., Jagannath S., et al. Stage I and II diffuse large cell lymphoma Prognostic factors and long term results with CHOP-Bleo and radiotherapy . Blood. 77:1991;942-947.
4. Fuller L.M., Krasin M.J., Velasquez W.S., et al. Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation. Int J Radiat Oncol Biol Phys. 31:1995;3-11.
5. Miller T.P., Dahlberg S., Cassady J.R., et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 339:1998;21-25.
6. Glick J.H., Kim K., Earl J. An ECOG randomized phase III trial of CHOP vs CHOP plus radiotherapy for intermediate grade early stage non-Hodgkin's lymphoma (Abstr.). Proc Am Soc Clin Oncol. 14:1995;391.
7. Lister T.A., Crowther D., Sutcliffe S.B., et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease Cotswolds meeting . J Clin Oncol. 7:1989;1630-1636.
8. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphoma Summary and description of a working formulation for clinical usage . Cancer. 49:1982;2112-2135.
9. Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 31:1995;1341-1346.
10. Tobinai K., Kohno A., Shimada Y., et al. Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 23:1993;250-257.
11. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 17:1999;1244-1253.
12. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;475-481.
13. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170.
14. Cox D.R. Regression models and life tables. JR Stat Soc [B]. 34:1972;187-202.
15. Tsutsui K., Shibamoto Y., Yamabe H., et al. A radiotherapeutic experience for localized extranodal non-Hodgkin's lymphoma Prognostic factors and re-evaluation of treatment modality . Radiother Oncol. 21:1991;83-90.
16. Kaminski M.S., Colemn C.N., Colby T.V., et al. Factors predicting survival in adults with stage I and II large cell lymphoma treated with primary radiation therapy. Ann Intern Med. 104:1986;747-756.
17. Nissen N.I., Ersboll J., Hansen H.S., et al. A randomized study of radiotherapy versus radiation plus chemotherapy in stage I-II non-Hodgkin's lymphoma. Cancer. 52:1983;1-7.
18. Jones S.E., Miller T.P., Connors J.M. Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol. 7:1989;1186-1191.
19. Longo D.L., Glatstein E., Duffey P.L., et al. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved field radiation therapy. J Clin Oncol. 7:1989;1295-1302.
20. Connors J.M., Klimo P., Fairey R.N., et al. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med. 107:1987;25-30.
21. Cosset J.M. Chemoradiotherapy for localized non-Hodgkin's lymphoma. N Engl J Med. 339:1998;44-45.
22. Mounier N., Morel P., Haioun C., et al. A multivariate analysis of the survival of patients with aggressive lymphoma Variations in the predictive value of prognostic factors during the course of the disease . Cancer. 82:1998;1952-1962.
23. Fisher R.I., Gaynor E.R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 328:1993;1002-1006.